Josep M. Llovet, MD, PhD
The recent addition of multikinase inhibitors and immunotherapies has moved the needle in the right direction for hepatocellular carcinoma (HCC), but the next steps involve sequencing these agents and incorporating combination regimens.
According to Josep M. Llovet, MD, PhD, there are several promising approaches with checkpoint inhibitors being tested in phase III studies. For example, the frontline combination of the PD-L1 inhibitor atezolizumab (Tecentriq) and bevacizumab (Avastin) was granted a breakthrough therapy designation for patients with advanced or metastatic HCC.
A phase Ib study presented at the 2018 ESMO Congress showed that atezolizumab plus bevacizumab induced a confirmed investigator-assessed objective response rate of 32% per RECIST v1.1 criteria in patients with advanced HCC, with more than half of responders maintaining their response for at least 6 months and about one-fourth for at least 12 months.
... to read the full story